Cerdulatinib
Cerdulatinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase JAK1, NUAK family SNF1-like kinase 1, non-receptor tyrosine-protein kinase TYK2, tyrosine-protein kinase SYK, mitogen-activated protein kinase kinase kinase 9, macrophage colony-stimulating factor 1 receptor, tyrosine-protein kinase JAK2, tyrosine-protein kinase JAK3, and serine/threonine-protein kinase 4.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 1
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | CERDULATINIB |
INN | cerdulatinib |
Description | Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies. It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK.
|
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1 |
Identifiers
PDB | — |
CAS-ID | 1198300-79-6 |
RxCUI | — |
ChEMBL ID | CHEMBL4116008 |
ChEBI ID | — |
PubChem CID | 44595079 |
DrugBank | DB15499 |
UNII ID | D1LXQ45S1O (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
JAK1
JAK1
NUAK1
NUAK1
TYK2
TYK2
SYK
SYK
MAP3K9
MAP3K9
CSF1R
CSF1R
JAK2
JAK2
JAK3
JAK3
STK4
STK4
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 210 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more